MetaCap

Jaguar Health Inc. (JAGX)

NASDAQ: JAGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.227-0.10 (-30.58%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

JAGX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$257.15
52-week range
0.22 – 981.75
Day range
0.22 – 0.3278
Volume / Avg
987.20K / 2.40M
Beta
—

52-week range

$0.22$981.75

JAGX stock today

Jaguar Health (JAGX) closed at $0.227 on Nov 20, down 30.58% (-$0.10), versus the S&P 500's 3.70% decline. Trading was light, with 987.20K shares changing hands, about 41% of the average daily volume. At this level, JAGX sits near the bottom of its 52-week range of $0.22 to $981.75: 100.0% below the high and 3.2% above the low.

Jaguar Health has posted a net loss over the last twelve months (EPS of -$257.15), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Jaguar Health

Company profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Lisa A. Conte
Headquarters
San Francisco, CA
Employees
47
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Jaguar Health generated $11.5 million in revenue, down 1.5% from fiscal 2024, its first annual decline since 2023. Jaguar Health reported a net loss of $53.6 million, compared with a loss of $38.5 million a year earlier. Gross margin was 67.2% (down from 83.3%) and operating margin -398.8%.

Jaguar Health annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$11.51M$11.69M$9.76M$11.96M$4.33M
Growth-1.52%+19.75%-18.36%+175.80%-53.81%
Net income$-53.58M$-38.49M$-41.90K$-48.40K$-52.60K
EPS (diluted)$-22.97$-130.69$-2,678.17$-36.18$-88.22

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-9.23 vs —

JAGX news

All JAGX news

Jaguar Health peers

Health Care sector
JAGX peer companies
CompanyPrice% ChgMarket capCompare
SKYESkye Bioscience Inc.0.70-11.03%$3.10Mvs JAGX
APUSApimeds Pharmaceuticals US Inc.1.60-8.05%$2.96Mvs JAGX
GELSGelteq Limited0.2701-3.74%$3.11Mvs JAGX
AZTRAzitra Inc0.5168-2.75%$3.13Mvs JAGX
MDCXMedicus Pharma Ltd.1.14-2.16%$3.16Mvs JAGX
KPRXKiora Pharmaceuticals Inc.0.7202-12.28%$3.19Mvs JAGX
NRSNNeuroSense Therapeutics Ltd.1.28+1.59%$3.19Mvs JAGX
APREAprea Therapeutics Inc.0.229-53.56%$3.25Mvs JAGX

Indexes, lists and sector

Jaguar Health stock FAQ

What is Jaguar Health's stock price today?

JAGX last traded at $0.227 as of Nov 20, 4:00 PM EST, down 30.58% on the day. Prices are delayed at least 15 minutes.

Who is Jaguar Health's CEO?

Ms. Lisa A. Conte is the chief executive officer of Jaguar Health Inc., which has about 47 employees.

What is the JAGX 52-week high?

The 52-week high for JAGX is $981.75 and the 52-week low is $0.22. The stock is currently 100.0% below its high.

Compare JAGX